High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M™, with Seasonal Administration to Children in Burkina Faso

2021 ◽  
Author(s):  
Mehreen S. Datoo ◽  
Hamtandi Magloire Natama ◽  
Athanase Somé ◽  
Ousmane Traoré ◽  
Toussaint Rouamba ◽  
...  
Keyword(s):  
Burkina Faso ◽  
Malaria Vaccine ◽  
Low Dose ◽  
High Efficacy ◽  
Candidate Malaria Vaccine

A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.

1999 ◽  
Vol 61 (6) ◽  
pp. 865-868 ◽  
Author(s):  
J F Doherty ◽  
B M Greenwood ◽  
C A Holland ◽  
J Cohen ◽  
P Momin ◽  
...  
Keyword(s):  
Phase I ◽  
Malaria Vaccine ◽  
The Gambia ◽  
Candidate Malaria Vaccine

scholarly journals Passive Immunoprotection ofPlasmodium falciparum-Infected Mice Designates the CyRPA as Candidate Malaria Vaccine Antigen

2012 ◽  
Vol 188 (12) ◽  
pp. 6225-6237 ◽  
Author(s):  
Anita M. Dreyer ◽  
Hugues Matile ◽  
Petros Papastogiannidis ◽  
Jolanda Kamber ◽  
Paola Favuzza ◽  
...  
Keyword(s):  
Malaria Vaccine ◽  
Vaccine Antigen ◽  
Ofplasmodium Falciparum ◽  
Candidate Malaria Vaccine

scholarly journals OC 8582 A PHASE IA/B STUDY TO ASSESS SAFETY AND IMMUNOGENICITY OF PLACENTAL MALARIA VACCINE CANDIDATE: PRELIMINARY RESULTS OF THE PRIMALVAC TRIAL

2019 ◽  
Vol 4 (Suppl 3) ◽  
pp. A14.3-A15
Author(s):  
Amadou Konate ◽  
Laura Richert ◽  
Arnaud Chêne ◽  
Jean-Philippe Semblat ◽  
Gwenaelle Roguet ◽  
...  
Keyword(s):  
Adverse Events ◽  
Burkina Faso ◽  
Malaria Vaccine ◽  
Clinical Laboratory ◽  
Placental Malaria ◽  
Safety Data ◽  
Vaccine Trial ◽  
Adult Women ◽  
Serious Adverse Events ◽  
Double Blind

BackgroundAdhesion of P. falciparum-infected erythrocytes (PEs) to placental chondroitin-4-sulfate (CSA) has been linked to severe placental malaria (PM) outcomes. Evidence strongly supports the VAR2CSA variant surface antigen mediating PEs CSA-binding phenotype as the leading candidate for a PM vaccine. This study was conducted to assess the safety and immunogenicity of 3 different dosages (20 µg, 50 µg and 100 µg) of the recombinant VAR2CSA protein (PRIMVAC), formulated with Alhydrogel or GLA-SE administered at days 0, 28 and 56.MethodsA randomised double-blind phase Ia/Ib dose-escalation vaccine trial was conducted in healthy adult women. Within 4 sequential cohorts, volunteers were randomised to 2 arms (PRIMVAC adjuvanted with Alhydrogel or GLA-SE) in the first phase conducted in France and then to 3 arms (PRIMVAC with Alhydrogel or GLA-SE or placebo) in Burkina Faso. Enrolled volunteers were observed for at least 1 hour following each vaccination then seen at 1 day and 7 days later for safety evaluations. Serious adverse events (SAE) were recorded throughout the study duration. Routine clinical laboratory safety analyses were performed prior to first injection and at each subsequent visit.ResultsA total of 68 subjects were recruited in the four study cohorts. No SAE was reported in any of the cohort A volunteers and enrolment in cohort B was started. A Data Safety Monitoring Board (DSMB) reviewed the safety data for cohorts A (20 µg) and B (50 µg) before the trial was initiated in Burkina Faso. The DSMB also reviewed the safety data in Burkina to authorise the progression from the cohort C (50 µg) to cohort D (100 µg). The last vaccination of the last subject occurred in September 2017.ConclusionThis was the first placental malaria vaccine phase Ia/b clinical trial conducted in France and Burkina Faso. No serious adverse events have been recorded. Preliminary safety and immunogenicity results will be presented.

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults

Vaccine ◽  
2007 ◽  
Vol 25 (29) ◽  
pp. 5359-5366 ◽  
Author(s):  
Kent E. Kester ◽  
Denise A. McKinney ◽  
Nadia Tornieporth ◽  
Christian F. Ockenhouse ◽  
D. Gray Heppner ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Regimen ◽  
Malaria Vaccine ◽  
Randomized Study ◽  
Candidate Malaria Vaccine
Sign in / Sign up

Export Citation Format

Share Document